Pfizer’s Hospira Site in India Lands Another FDA Form 483

Pfizer’s Hospira Site in India Lands Another FDA Form 483

Source: 
RAPS.org
snippet: 

In a 32-page US Food and Drug Administration (FDA) Form 483, 11 citations revealed manufacturing and quality control issues at the Hospira Healthcare India facility in Tamil Nadu.